Clinical Trial Update: Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol [Phase 2]

View source ↗

Summary

This completed Phase 2 trial evaluated the efficacy and safety of AZD5423 in COPD patients who were receiving Formoterol as background therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• AZD5423
• Formoterol (formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Status: COMPLETED